重大事件
即時報告
8-K
2026-06-30
Rocket Pharmaceuticals 財務高層變動 任命 Joseph Manhede 為新任首席會計官
AI 繁中摘要
Rocket Pharmaceuticals（RCKT）於2026年6月24日向SEC提交8-K申報，披露財務高層人事變動。
原任財務副總裁、高級會計總監、財務主管及首席會計官John Militello已辭職，自7月7日起生效，以尋求其他發展機會。
公司隨即任命現任副總裁兼企業會計總監Joseph Manhede為新任首席會計官，自7月8日起生效。Manhede現年48歲，今年4月才加入Rocket，此前曾在Outlook Therapeutics擔任副總裁兼財務總監，負責會計、財務報告、SEC合規、內控、預算及策略財務規劃；亦曾在Amneal Pharmaceuticals、Unilife Corporation及Celator Pharmaceuticals擔任高級財務及會計職位，包括企業會計總監，在財務報告、IPO準備、SOX合規及收購整合方面經驗豐富。其職業生涯始於Deloitte審計經理，持有CPA資格及MBA學位。
公司強調，Manhede的任命不會觸發新的薪酬安排，與公司任何董事或高管無親屬關係，亦無須披露的關聯交易。
是次更換首席會計官屬正常人事接替，新任主管具備深厚的生物製藥財務背景，料不影響公司財務報告的連續性與合規水準。投資者應留意短期內財務領導層過渡情況，但整體風險可控。
展開英文正文
false000128189500012818952026-06-242026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2026 Rocket Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36829 04-3475813 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 9 Cedarbrook Drive, Cranbury, NJ 08512 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (609) 659-8001 Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. On June 24, 2026, John Militello informed Rocket Pharmaceuticals, Inc. (the “Company” or “Rocket”) of his resignation as VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, effective July 7, 2026, to pursue other opportunities. On June 30, 2026, Joseph Manhede, the Company’s Associate Vice President, Corporate Controller, was appointed as the Company’s Principal Accounting Officer, effective July 8, 2026. Mr. Manhede, age 48, has served as the Company’s Associate Vice President, Corporate Controller since April 2026. Prior to Rocket, Mr. Manhede was the Vice President and Financial Controller for Outlook Therapeutics, a clinical-stage biopharmaceutical company, where he was responsible for leading accounting and finance functions, including financial reporting, SEC compliance, internal controls, budgeting, and strategic financial planning, as well as supporting financing transactions and corporate governance initiatives. Prior to his time at Outlook, Mr. Manhede held senior finance and accounting positions at Amneal Pharmaceuticals, Unilife Corporation, and Celator Pharmaceuticals, Inc., where he served as Corporate Controller and played a key role in financial reporting, IPO readiness, SOX compliance, and acquisition integration. He began his career at Deloitte, where he served as an Audit Manager. Mr. Manhede is a Certified Public Accountant (CPA) and holds a Master of Business Administration from Holy Family University. No new compensatory arrangements will be entered into with Mr. Manhede in connection with his designation as the Company’s Principal Accounting Officer. There are no family relationships between Mr. Manhede and any other director or executive officer of the Company, and no transactions involving Mr. Manhede that would require disclosure under Item 404(a) of Regulation S-K. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: June 30, 2026 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer